GLP-1 receptor agonists × adverse events & safety

ArticleBMC endocrine disorders2015

The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls.

Hassan Kahal et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 2015

No range given

Reported higher adverse events & safety, no range given

+0.26

As reported

difference 0.26, no interval

+1 more in the walkthrough ↓

Two numbers in the abstract

the abstract, start to end

at six months in controls -0.17 ± 0.26 but not PCOS -0.12 ± 0.28;

mg od body weight was reduced by 3.0 ± 4.2 (P < 0.01) and 3.8 ± 3.4 kg

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Adverse events & safety
0.26
Adverse events & safety
−4.20
GLP-1 receptor agonistsAdverse events & safety

GLP-1 receptor agonists × adverse events & safetyharms?mixed

unlikelylikely
0.020.02 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

35 papers cite it

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled itcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 25880805